...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retina >A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration.
【24h】

A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration.

机译：对新生血管性黄斑变性患者三联联合玻璃体内注射贝伐单抗，后腱下曲安奈德和低通量维替泊芬光动力疗法的回顾性分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To assess the efficacy of triple combination therapy (TCT) including bevacizumab (BEV), low-fluence photodynamic therapy, and posterior sub-Tenon's triamcinolone acetonide in patients with wet age-related macular degeneration. METHODS: This institutional review board-approved retrospective consecutive case series included 31 eyes treated for wet age-related macular degeneration with TCT at the Beth Israel Deaconess Medical Center between June 2004 and November 2008. Outcome measures included visual acuity, retinal thickness as measured by optical coherence tomography, time to retreatment, and complications. RESULTS: Triple combination therapy eyes showed significant 3-month and 6-month improvement in visual acuity of 0.140 +/- 0.273 logarithm of the minimum angle of resolution and 0.182 +/- 0.383 logarithm of the minimum angle of resolution after treatment, respectively (P = 0.0219 and 0.0470, respectively). Central retinal thickness significantly improved at 3 months (-123.8 +/- 102.7 mum), 6 months (-87.7 +/- 99.8 mum), and 12 months (-101.6 +/- 103.3 mum) on optical coherence tomography. Half of eyes that underwent TCT required retreatment by the conclusion of their follow-up, and eyes that underwent TCT had a 1-year Kaplan-Meier survival rate of 62.1 +/- 10.8%. CONCLUSION: Triple combination therapy (TCT) appears to effectively improve visual acuity and decrease retinal thickness often without need for subsequent retreatment within the first year of follow-up. Further investigation of TCT in prospective trials is warranted.
机译：目的：评估三联疗法（TCT），包括贝伐单抗（BEV），低通量光动力疗法和后特农氏曲安奈德治疗湿性老年性黄斑变性的疗效。方法：该机构审查委员会批准的回顾性连续病例系列研究，包括2004年6月至2008年11月间在贝斯以色列女执事医疗中心接受TCT治疗的湿性年龄相关性黄斑变性的31只眼睛。结果包括视力，视网膜厚度光学相干断层扫描，再治疗时间和并发症。结果：三联联合治疗后，治疗后3个月和6个月的视力分别显着改善，最小分辨角为0.140 +/- 0.273对数，最小分辨角为0.182 +/- 0.383对数（ P分别为0.0219和0.0470）。光学相干断层扫描在3个月（-123.8 +/- 102.7微米），6个月（-87.7 +/- 99.8微米）和12个月（-101.6 +/- 103.3微米）时视网膜中央厚度明显改善。接受TCT的眼睛中有一半需要在随访结束时进行治疗，接受TCT的眼睛的1年Kaplan-Meier生存率为62.1 +/- 10.8％。结论：三联联合疗法（TCT）似乎可以有效地提高视力并减少视网膜厚度，通常不需要在随访的第一年内进行后续治疗。有必要在前瞻性试验中进一步研究TCT。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号